

Attorney Docket No.: 47234-0003-00-US
Application No. 10/500,841
Reply to Office Action Dated: July 11, 2008
Amendment Dated: December 11, 2008

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-5. (Canceled)

Claim 6. (Previously Presented): A pharmaceutical composition comprising an amount of the polypeptide fragment of claim 25 sufficient to accelerate neovascularization, and a pharmaceutically acceptable carrier.

Claim 7. (Currently Amended): ~~A wound healing agent comprising a pharmaceutically effective pharmaceutical composition comprising an~~ amount of the polypeptide fragment of claim 25 sufficient to promote wound healing and a pharmaceutically acceptable carrier.

Claims 8-22. (Canceled)

Claim 23. (Withdrawn – Currently Amended): A method for accelerating neovascularization comprising administering an ~~effective~~ amount of the polypeptide fragment of claim 25 sufficient to accelerate neovascularization and a pharmaceutically acceptable carrier therefor to a mammal.

Claim 24. (Currently Amended): ~~An agent for treating arteriosclerosis containing a pharmaceutically effective~~ A pharmaceutical composition comprising an amount of the polypeptide fragment of claim 25 sufficient to treat arteriosclerosis and a pharmaceutically acceptable carrier therefor.

Claim 25. (Previously Presented): A polypeptide fragment of an N-acetylglucosaminyl-transferase V (GnT-V), comprising a basic amino acid cluster region,

Attorney Docket No.: 47234-0003-00-US
Application No. 10/500,841
Reply to Office Action Dated: July 11, 2008
Amendment Dated: December 11, 2008

wherein the basic amino acid cluster region comprises the amino acid sequence of SEQ ID NO: 7 and up to 50 contiguous amino acids encoded by the sequence shown in SEQ ID NO: 6, or a variant thereof,

wherein the polypeptide fragment or variant thereof possesses neovascularization activity,

wherein the number of amino acids modified by addition, removal, or substitution in the variant is up to 10% of the number of amino acids in the basic amino acid cluster region, and

wherein the addition, removal, or substitution is conducted on amino acids other than basic amino acids.

Claim 26. (Previously Presented): The polypeptide of claim 25, wherein one amino acid other than a basic amino acid of the variant is added, removed, or substituted from the amino acid sequence encoded by the sequence shown in SEQ ID NO: 6.

Claim 27. (Previously Presented): The polypeptide of claim 25, wherein the number of basic amino acids accounts for greater than 30% of the total number of amino acids in said fragment.

Claim 28. (Canceled).

Claim 29. (Previously Presented): The polypeptide of claim 25, consisting of the amino acid sequence shown in SEQ ID NO: 7.

Claim 30. (Currently Amended): A pharmaceutical composition comprising a ~~pharmaceutically effective~~ an amount of a ~~polypeptide consisting of SEQ ID NO: 11 or a~~ polypeptide consisting of SEQ ID NO: 7 sufficient to accelerate neovascularization.